CARMELIET PETER has a total of 14 patent applications. Its first patent ever was published in 2001. It filed its patents most often in United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are GENOMIX CO LTD, APOTECH SA and UNIV GEORGETOWN MED CENTER.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 10 | |
#2 | WIPO (World Intellectual Property Organization) | 4 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Agriculture | |
#5 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Analysing materials | |
#5 | Microorganisms | |
#6 | Animal care | |
#7 | Measuring microorganism processes | |
#8 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Carmeliet Peter | 14 |
#2 | Collen Desire | 6 |
#3 | Menotti Ruvo | 4 |
#4 | De Falco Sandro | 4 |
#5 | Loges Sonja | 2 |
#6 | Scherer Stefan | 1 |
#7 | Luttun Aernout | 1 |
#8 | Lambrechts Diether | 1 |
#9 | Oosthuyse Bert | 1 |
#10 | Herbert Corentin | 1 |
Publication | Filing date | Title |
---|---|---|
WO2010037864A2 | Inhibition of plgf to treat philadelphia chromosome positive leukemia | |
WO0156593A2 | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke |